Abstract
Information on human genetic variance is only just beginning to be used in drug development.
References
Putney, S.D. et al. Nature 302, 718–721 (1983).
Cooper, T.A. et al. Science 226, 979–982 (1984).
Zipkin, I. et al. BioCentury Oct. 20, A5 (1997).
Reddy D.S. et al. Methods Find. Exp. Clin. Pharmacol. 18, 261– 271 (1996).
Jerkovic, R. et al. Cell Struct. Funct. 22, 147– 153 (1997).
Olschwang, S. et al. Proc. Natl. Acad. Sci. USA 94, 12122– 12127(1997).
Persidis, A. Nat. Biotechnol. 15, 1409–1411 (1997).
Rioux, P.P. Am. J. Health Syst. Pharm. 57, 887– 898 (2000).
McCarthy, J.J. & Hilfiker, R. Nat. Biotechnol. 18 , 505–508 (2000).
Issa, A.M. Trends Pharmacol. Sci. 21, 247–249 (2000).
Rights and permissions
About this article
Cite this article
Pharmacogenomics. Nat Biotechnol 18 (Suppl 10), IT40–IT42 (2000). https://doi.org/10.1038/80079
Issue Date:
DOI: https://doi.org/10.1038/80079
- Springer Nature America, Inc.
This article is cited by
-
Ethical perspectives on pharmacogenomic profiling in the drug development process
Nature Reviews Drug Discovery (2002)